Cargando…

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up

Background. OT101 is a first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of transforming growth factor beta 2 (TGFβ2). Here, we report our post-hoc analysis of the single-agent activity of OT101 in adult patients with recurrent and/or refractory (R/R) high-grade gliom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uckun, Fatih M., Qazi, Sanjive, Hwang, Larn, Trieu, Vuong N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966490/ https://www.ncbi.nlm.nih.gov/pubmed/31795071 http://dx.doi.org/10.3390/cancers11121892

Ejemplares similares

High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma
por: Uckun, Fatih M., et al.
Publicado: (2023)

Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer
por: D’Cruz, Osmond J, et al.
Publicado: (2018)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

Convection Enhanced Delivery in the Setting of High-Grade Gliomas
por: Nwagwu, Chibueze D., et al.
Publicado: (2021)

Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma
por: Sperring, Colin P, et al.
Publicado: (2023)

Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies
por: Uckun, Fatih M., et al.
Publicado: (2014)

Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas
por: Wang, Joshua L., et al.
Publicado: (2020)

Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator()
por: Uckun, Fatih M., et al.
Publicado: (2014)

Convection-enhanced drug delivery for gliomas
por: Healy, Andrew T., et al.
Publicado: (2015)

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
por: Uckun, Fatih M., et al.
Publicado: (2021)

Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL
por: Uckun, Fatih M., et al.
Publicado: (2015)

Convection-enhanced Delivery of Therapeutics for Malignant Gliomas
por: SAITO, Ryuta, et al.
Publicado: (2017)

Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients
por: Uckun, Fatih M., et al.
Publicado: (2013)

Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma
por: Saito, Ryuta, et al.
Publicado: (2020)

Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment
por: Zhou, Zhiping, et al.
Publicado: (2017)

EPCT-18. A TWO-PART, PHASE 1 STUDY OF RHENIUM-186 NANOLIPOSOME (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY FOR RECURRENT, REFRACTORY, OR PROGRESSIVE EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG) AND NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Plant, Ashley, et al.
Publicado: (2021)

TIPS-22 A TWO-PART, PHASE 1 STUDY OF RHENIUM (186RE) OBISBEMEDA (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) FOR RECURRENT, REFRACTORY, OR PROGRESSIVE CHILDHOOD EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG)
por: Plant, Ashley, et al.
Publicado: (2023)

Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy
por: Shi, Minghan, et al.
Publicado: (2019)

Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience
por: Upadhyayula, Pavan S., et al.
Publicado: (2020)

INSP-17. Augmented Drug Delivery for Pediatric Diffuse Midline Glioma using Convection Enhanced Delivery
por: Souweidane, Mark M
Publicado: (2022)

Realizing the Potential for Recipient Immune Cells in Adoptive Immune Therapy
por: Qazi, Sanjive
Publicado: (2016)

Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging
por: Nwagwu, Chibueze D., et al.
Publicado: (2020)

Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience
por: Grahn, Amy Y., et al.
Publicado: (2009)

Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience
por: Tosi, Umberto, et al.
Publicado: (2020)

ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma
por: Sasaki, Takahiro, et al.
Publicado: (2020)

Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance
por: Wang, Yongheng, et al.
Publicado: (2021)

Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma
por: Hollingworth, Milo, et al.
Publicado: (2022)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Sasaki, Takahiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39b90p907d3pkkobkp9g35m9s0